IL-1 inhibition with anakinra in a patient with refractory gout.
Singh
Dushyant
D
Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Huston
K Kwasind
KK
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1